Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The TAM tyrosine kinase receptors TYRO3, AXL and MERTK regulate tissue and immune homeostasis. This Review discusses how their aberrant signalling is linked to diseases such as cancer, fibrosis and viral infection, and surveys the therapeutic landscape of TAM receptor inhibitors in preclinical and clinical development.
Advances with deep learning, the growth of databases of molecules for virtual screening and improvements in computational power have supported the emergence of a new field of quantitative structure–activity relationship (QSAR) modelling applications that Tropsha et al. term ‘deep QSAR’. This article discusses key advances in the field, including deep generative and reinforcement learning approaches in molecular design, deep learning models for synthetic planning, and the use of deep QSAR models in structure-based virtual screening.
A diverse range of systems have recently been developed to promote the degradation of extracellular and membrane protein targets by using bispecific antibodies, conjugates or small molecules to traffic targeted proteins to the lysosome. This article describes and categorizes systems for extracellular targeted protein degradation, including LYTACs, ATACs, AbTACs, PROTABs and KineTACs, and discusses their advantages and the challenges ahead to realizing their therapeutic potential.
The potential of harnessing tRNAs to treat genetic diseases has recently gained significant attention. Here, Coller and Ignatova provide an overview of the history and potential applications of tRNA-based therapies, summarize advances in tRNA cargo design and delivery strategies, and assess the challenges encountered in establishing tRNAs as effective and safe therapeutics.